ACETREN – Trenbolone Acetate 120mg/ml 5x2ml Box
PHARMACEUTICAL NAME: Trenbolone Acetate
MOLECULAR STRUCTURE: C20-H24-03
PROPRIETARY NAME: ACETREN
DOSAGE FORM: 120 mg/ml injection
COMPOSITION: Each ml of ACETREN contains Trenbolone Acetate in oil base q.s.
PHARMACOLOGICAL CLASSIFICATION: Anabolic Steroids
Trenbolone acetate, when injected, provides a peak release of the base steroid, about one day after injection. Trenbolone acts similarly to testosterone, although it has a binding affinity for the androgen receptor five times as high as that of testosterone. It does also carry a more favorable balance towards anabolism than androgenism. Once metabolized, the drug has the effect of increasing nitrogen uptake by muscles, leading to an increase in the rate of protein synthesis. It also has the secondary effects of stimulating appetite, reducing the amount of fat being deposited in the body, and decreasing the rate of catabolism. Trenbolone has proven safer with users as it is not metabolized by aromatase or 5 areductase into estrogenic compounds such as estradiol, or into DHT. This means that it also does not cause any water retention normally associated with highly androgenic steroidal compounds like methandrostenolone. Trenbolone and it’s derivative 17 epitrenbolone are both excreted in urine as conjugates that can be hydrolyzed with betaglucuronidase. This implies that trenbolone leaves the body as betaglucuronidase or sulfates. Trenbolone acetate has a half life of 2-3 days.
Males: Trenbolone is indicated for increasing muscular mass, hardness and without water retention and now estrogenic activity, as well as increasing the metabolic rate, which means an increase of the fat burning rate.
Females: Since women will suffer virilization effects even at small doses, this drug should not be taken by a female.
Trenbolone is contradicted in men with carcinomas of the breast or with known or suspected carcinomas of the prostate or liver/renal disease and in women in general. Also in men with hypersensitivity to the drug or any of it’s excipients. Trenbolone, through its metabolic effects, stimulates the nervous, mental, and physical activities of a patient. Therefore, it should be used with caution in the presence of cardiovascular and renal diseases, especially in the elderly male. Prolonged administration or excessive dosage may cause inhibition of testicular function. As a result, oligospermia may develop, and there may be a decrease in ejaculatory volume. Anaphylactoid reactions, although rare, may occur, and treatment should be readily available. Hypersensitivity reactions, including rash and dermatitis, have been reported.
Women should be observed for signs of virilization. Discontinuation of drug therapy at the mild virilism becomes evident is necessary to prevent irreversible virilization. Such virilization usually follows administration of androgens at high doses. Adecision may be made by the patient and the physician concerning the degree of virilization that will be toleranted during treatment for breast carcinoma.
Anaphylactoid reactions, although rare, may occur, and treatment should be readily available. Hypersensitivity reactions, including rash and dermatitis, have been reported.
DOSAGE AND DIRECTIONS FOR USE:
ACETREN is administrated by intramuscular injection. Intramuscular injections should be given deep in the gluteal muscle.
Male: 120-360 mg per week, given 3 times weekly.
In diabetic patients, the metabolic effects of ACETREN may decrease blood glucose and insulin requirements.
If overdose is suspected, contact your local hospital immediately.
Store in a cool dry place below 25 °C.
Not to be refrigerated.
Protect from light.
Keep out of reach of children.
BOX: 5 vials of 2 ml (120 mg/ml)
Pharmed Corporation Ltd., 3361/A, Rani Bagh, Mahindra Park Rajdhani Enclave, Shakurpur, New Delhi, Delhi 110034, India tel +919953242466, https://pharmed-corp.com
DATE OF PUBLICATION OF THIS PACKAGE INSERT: